News
CRTHF
1.920
NaN%
--
CARsgen Therapeutics Holdings Ltd. (2171) Receives a Sell from Goldman Sachs
TipRanks · 08/20 11:16
CARsgen narrows loss and boosts cash on CAR T sales and top-up placing
TipRanks · 08/18 14:38
CARsgen Wins NMPA IND Clearance for Allogeneic CAR T Therapy CT1190B in R/R Large B-Cell Lymphoma
TipRanks · 08/07 00:09
CARsgen’s Solid-Tumor CAR T Therapy Satri-cel Gains ESMO 2026 Spotlight
TipRanks · 07/15 00:07
CARsgen Launches Discretionary Share Buyback Worth Up to 5% of Capital
TipRanks · 06/26 04:38
UBS Remains a Buy on CARsgen Therapeutics Holdings Ltd. (2171)
TipRanks · 06/24 00:25
CARsgen Wins First-Ever Global Approval for Solid-Tumor CAR T Therapy in China
TipRanks · 06/22 08:42
CARsgen Advances Allogeneic CAR T Programs After Positive Early Data at EHA 2026
TipRanks · 06/15 00:07
CARsgen Showcases New Satri-cel Data as It Expands Claudin18.2 CAR T Strategy
TipRanks · 06/01 00:07
CARsgen completes HK$19.84-per-share placing and top-up subscription
TipRanks · 05/26 15:22
CARsgen Adds Directors’ Responsibility Statement to Share Placement Disclosure
TipRanks · 05/22 13:42
CARsgen Shareholders Back All AGM Resolutions, Strengthening Board Mandates and Governance
TipRanks · 05/22 13:41
CARsgen Raises Capital via Discounted Share Placing to Accelerate Global CAR T R&D
TipRanks · 05/15 00:07
CARsgen Advances Allogeneic CAR T Programs as EHA Accepts New Data for 2026
TipRanks · 04/27 11:08
CARsgen Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority
TipRanks · 04/10 13:46
UBS Sticks to Its Buy Rating for CARsgen Therapeutics Holdings Ltd. (2171)
TipRanks · 03/21 00:26
CARsgen Grants 4.27 Million Share Options Under Post-IPO Incentive Scheme
TipRanks · 03/09 14:39
CARsgen Shares Added to Southbound Stock Connect, Opening Door to Mainland Investors
TipRanks · 03/09 00:07
CARsgen Narrows 2025 Loss as CAR-T Therapy Sales Grow and Costs Fall
TipRanks · 03/06 12:12
CARsgen Schedules Board Meeting to Approve 2025 Annual Results
TipRanks · 02/24 10:37
More
Webull provides a variety of real-time CRTHF stock news. You can receive the latest news about CARsgen through multiple platforms. This information may help you make smarter investment decisions.
About CRTHF
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.